Classification and Treatment of Rare and Aggressive Types of Peripheral T-Cell/Natural Killer-Cell Lymphomas of the Skin

Abstract

Background

The classification of cutaneous lymphomas has been contentious. Two major competing classifications were the World Health Organization (WHO) and the European Organization for Research and Treatment of Cancer (EORTC). The principal authors met for a consensus meeting resulted in a combined classification called WHO-EORTC Classification of Cutaneous Lymphoma.

Methods

We review the classification of “mature” or peripheral T-cell lymphoma (PTCL) with high predilection to the skin as published by the WHO-EORTC. We also highlight new information and changes from the previous classifications of cutaneous PTCL according to the WHO classification or the EORTC classification. Finally, the salient findings are compared with similar-looking nodal PTCLs with a high frequency of skin involvement.

Results

This review focuses on a rare group of cutaneous PTCLs other than mycosis fungoides or its variants. Changes from the previous classifications are discussed, and the rare group of nodal PTCLs with high predilection to the skin are presented. The salient findings, diagnostic features, and treatments are included, along with summary tables and clinical-histopathologic images.

Conclusions

This review may serve as a guide for hematologists, oncologists and dermatologists in the diagnosis and management of these rare, aggressive, and often difficult to diagnose lymphomas. Although cutaneous lymphomas are morphologically identical to systemic lymphomas, the former behave differently, require divergent management, and should be recognized as separate entities. The consensus WHO-EORTC classification presents unified terminology and definitions to promote conformity in diagnosing and treating these cases, to foster a multidisciplinary approach to these often-obscure diseases, and to lead to more advances in identifying molecular targets specific to these entities.

References

A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma.

The Non-Hodgkin's Lymphoma Classification Project.

Blood. 1997; 89: 3909–3918.

Groves

F.D.

, Linet

M.S.

, Travis

L.B.

. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histological subtype in the United States from 1978 through 1995. J Natl Cancer Inst. 2000; 92: 1240–1251.

Dores

G.M.

, Anderson

W.F.

, Devesa

S.S.

. Cutaneous lymphomas reported to the National Cancer Institute's Surveillance, Epidemiology, and End Results Program: applying the new WHO-European Organisation for Research and Treatment of Cancer classification system. J Clin Oncol. 2005; 23: 3390–3395.

Willemze

, Jaffe

E.S.

, Burg

. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005; 105: 3768–3785. Epub 2005 Feb 3.

Burg

, Kempf

, Cozzio

. WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. J Cutan Pathol. 2005; 32: 647–674.

Kim

E.J.

, Hess

, Richardson

S.K.

. Immunopathogenesis and therapy of cutaneous T-cell lymphoma. J Clin Invest. 2005; 115: 798–812.

Hudak

, Hagen

, Liu

. Immune surveillance and effector functions of CCR10 (+) skin homing T cells. J Immunol. 2002; 169: 1189–1196.

Kabelitz

, Marischen

, Oberg

H.H.

. Epithelial defence by gamma delta T cells. Int Arch Allergy Immunol. 2005; 137: 73–81. Epub 2005 Apr 12.

Lanier

L.L.

. NK cell recognition. Annu Rev Immunol. 2005; 23: 225–274.

10.

Alibert

J.L.M.

. Description des Maladies de la Peau Observees a l'Hopital St. Louis. Barrois L'aine et Fils. 1806: 413–446.

11.

Willemze

, Meijer

C.J.

. Classification of cutaneous T-cell lymphoma: from Alibert to WHO-EORTC. J Cutan Pathol. 2006; 33(Suppl 1): 18–26.

12.

Edelson

R.L.

. Cutaneous T-cell lymphoma: mycosis fungoides, Sezary syndrome, and other variants. J Am Acad Dermatol. 1980; 2: 89–106.

13.

Lennert

. Non-Hodgkin's lymphomas: principles and application of the Kiel classification [in German]. Verh Dtsch Ges Pathol. 1992; 76: 1–13.

14.

Rilke

, Giardini

. Working formulation of malignant lymphomas for clinical use [in Italian]. Pathologica. 1982; 74: 151–160.

15.

Harris

N.L.

, Jaffe

E.S.

, Stein

. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994; 84: 1361–1392.

16.

Willemze

, Kerl

, Sterry

. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood. 1997; 90: 354–371.

17.

Jaffe

ES H.N.

, Stein

, Vardiman

J.W.

, eds. World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.

18.

Toro

J.R.

, Liewehr

D.J.

, Pabby

. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood. 2003; 101: 3407–3412. Epub 2003 Jan 9.

19.

Santucci

, Pimpinelli

, Massi

. Cytotoxic/natural killer cell cutaneous lymphomas: report of EORTC Cutaneous Lymphoma Task Force Workshop. Cancer. 2003; 97: 610–627.

20.

Bekkenk

M.W.

, Vermeer

M.H.

, Jansen

P.M.

. Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients. Blood. 2003; 102: 2213–2219. Epub 2003 May 15.

21.

W.Y.

, Ma

S.Y.

, Chim

C.S.

. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol. 2005; 16: 206–214.

22.

Berti

, Tomasini

, Vermeer

M.H.

. Primary cutaneous CD8-positive epidermotropic cytotoxic T-cell lymphomas. A distinct clinicopatho-logical entity with an aggressive clinical behavior. Am J Pathol. 1999; 155: 483–492.

23.

Massone

, Chott

, Metze

. Subcutaneous, blastic natural killer (NK), NK/T-cell, and other cytotoxic lymphomas of the skin: a morphologic, immunophenotypic, and molecular study of 50 patients. Am J Surg Pathol. 2004; 28: 719–735.

24.

Lozzi

G.P.

, Massone

, Citarella

. Rimming of adipocytes by neoplastic lymphocytes: a histopathologic feature not restricted to subcutaneous T-cell lymphoma. Am J Dermatopathol. 2006; 28: 9–12.

25.

Marzano

A.V.

, Berti

, Paulli

. Cytophagic histiocytic panniculi-tis and subcutaneous panniculitis-like T-cell lymphoma: report of 7 cases. Arch Dermatol. 2000; 136: 889–896.

26.

Salhany

K.E.

, Macon

W.R.

, Choi

J.K.

. Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta subtypes. Am J Surg Pathol. 1998; 22: 881–893.

27.

Ghobrial

I.M.

, Weenig

R.H.

, Pittlekow

M.R.

. Clinical outcome of patients with subcutaneous panniculitis-like T-cell lymphoma. Leuk Lymphoma. 2005; 46: 703–708.

28.

R.S.

, Wester

S.M.

. Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis-like T-cell lymphoma: a systematic analysis of 156 patients reported in the literature. Cancer. 2004; 101: 1404–1413.

29.

Craig

A.J.

, Cualing

, Thomas

. Cytophagic histiocytic panniculitis—a syndrome associated with benign and malignant panniculitis: case comparison and review of the literature. J Am Acad Dermatol. 1998; 39 (5 pt 1): 721–736.

30.

Massone

, Lozzi

G.P.

, Egberts

. The protean spectrum of non-Hodgkin lymphomas with prominent involvement of subcutaneous fat. J Cutan Pathol. 2006; 33: 418–425.

31.

Slater

D.N.

. The new World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas: a practical marriage of two giants. Br J Dermatol. 2005; 153: 874–880.

32.

Kadin

M.E.

. Cutaneous gamma delta T-cell lymphomas: how and why should they be recognized? Arch Dermatol. 2000; 136: 1052–1054.

33.

Toro

J.R.

, Beaty

, Sorbara

. Gamma delta T-cell lymphoma of the skin: a clinical, microscopic, and molecular study. Arch Dermatol. 2000; 136: 1024–1032.

34.

Zucca

, Zinzani

P.L.

. Understanding the group of peripheral T-cell lymphomas, unspecified. Curr Hematol Rep. 2005; 4: 23–30.

35.

Savage

K.J.

, Chhanabhai

, Gascoyne

R.D.

. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004; 15: 1467–1475.

36.

Fink-Puches

, Zenahlik

, Back

. Primary cutaneous lymphomas: applicability of current classification schemes (European Organization for Research and Treatment of Cancer, World Health Organization) based on clinicopathologic features observed in a large group of patients. Blood. 2002; 99: 800–805.

37.

Rizvi

M.A.

, Evens

A.M.

, Tallman

M.S.

. T-cell non-Hodgkin lymphoma. Blood. 2006; 107: 1255–1264. Epub 2005 Oct 6.

38.

Setoyama

, Katahira

, Kanzaki

. Clinicopathologic analysis of 124 cases of adult T-cell leukemia/lymphoma with cutaneous manifestations: the smouldering type with skin manifestations has a poorer prognosis than previously thought. J Dermatol. 1999; 26: 785–790.

39.

Huber

M.A.

, Staib

, Pehamberger

. Management of refractory early-stage cutaneous T-cell lymphoma. Am J Clin Dermatol. 2006; 7: 155–169.

40.

Marzano

A.V.

, Ghislanzoni

, Gianelli

. Fatal CD8+ epider-motropic cytotoxic primary cutaneous T-cell lymphoma with multiorgan involvement. Dermatology. 2005; 211: 281–285.

41.

von den Driesch

, Coors

E.A.

. Localized cutaneous small to medium-sized pleomorphic T-cell lymphoma: a report of 3 cases stable for years. J Am Acad Dermatol. 2002; 46: 531–535.

42.

Mraz-Gernhard

, Natkunam

, Hoppe

R.T.

. Natural killer/natural killer-like T-cell lymphoma, CD56+, presenting in the skin: an increasingly recognized entity with an aggressive course. J Clin Oncol. 2001; 19: 2179–2188.

43.

Friedmann

, Wechsler

, Delfau

M.H.

. Primary cutaneous pleo-morphic small T-cell lymphoma. A review of 11 cases. The French Study Group on Cutaneous Lymphomas. Arch Dermatol. 1995; 131: 1009–1015.

44.

Gniadecki

, Rossen

, Ralfkier

. CD56+ lymphoma with skin involvement: clinicopathologic features and classification. Arch Dermatol. 2004; 140: 427–436.

45.

Pol-Rodriguez

M.M.

, Fox

L.P.

, Sulis

M.L.

. Extranodal nasal-type natural killer T-cell lymphoma in an adolescent from Bangladesh. J Am Acad Dermatol. 2006; 54 (5 suppl): S192–S197.

46.

Chan

J.K.

, Sin

V.C.

, Wong

K.F.

. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood. 1997; 89: 4501–4513.

47.

Cheung

M.M.

, Chan

J.K.

, Wong

K.F.

. Natural killer cell neoplasms: a distinctive group of highly aggressive lymphomas/leukemias. Semin Hematol. 2003; 40: 221–232.

48.

Bekkenk

M.W.

, Jansen

P.M.

, Meijer

C.J.

. CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol. 2004; 15: 1097–1108.

49.

Dummer

, Potoczna

, Haffner

A.C.

. A primary cutaneous non-T, non-B CD4+, CD56+ lymphoma. Arch Dermatol. 1996; 132: 550–553.

50.

Pagano

, Gallamini

, Trape

. NK/T-cell lymphomas ‘nasal type’: an Italian multicentric retrospective survey. Ann Oncol. 2006; 17: 794–800. Epub 2006 Feb 23.

51.

Siu

L.L.

, Wong

K.F.

, Chan

J.K.

. Comparative genomic hybridization analysis of natural killer cell lymphoma/leukemia. Recognition of consistent patterns of genetic alterations. Am J Pathol. 1999; 155: 1419–1425.

52.

Hoshida

, Hongyo

, Jia

. Analysis of p53, K-ras, c-kit, and beta-catenin gene mutations in sinonasal NK/T-cell lymphoma in northeast district of China. Cancer Sci. 2003; 94: 297–301.

53.

Chim

C.S.

, Ma

S.Y.

, Au

W.Y.

. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood. 2004; 103: 216–221. Epub 2003 Aug 21.

54.

Shimoyama

. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991; 79: 428–437.

55.

Cheung

M.M.

, Chan

J.K.

, Lau

W.H.

. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunopheno-type, and treatment outcome in 113 patients. J Clin Oncol. 1998; 16: 70–77.

56.

Gallamini

, Stelitano

, Calvi

. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multi-centric clinical study. Blood. 2004; 103: 2474–2479. Epub 2003 Nov 26.

57.

Gisselbrecht

, Gaulard

, Lepage

. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood. 1998; 92: 76–82.

58.

Coiffier

, Brousse

, Peuchmaur

. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives). Ann Oncol. 1990; 1: 45–50.

59.

Peipp

, Kupers

, Saul

. A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells. Cancer Res. 2002; 62: 2848–2855.

60.

Stadler

, Kremer

. Therapeutic advances in cutaneous T-cell lymphoma (CTCL): from retinoids to rexinoids. Semin Oncol. 2006; 33 (1 suppl 3): S7–S10.

61.

Foss

. Immunomodulatory effects of rexinoids. Semin Oncol. 2006; 33 (1 suppl 3): S21–S25.

62.

Dummer

. Future perspectives in the treatment of cutaneous T-cell lymphoma (CTCL). Semin Oncol. 2006; 33 (1 suppl 3): S33–S36.

63.

Duvic

, Talpur

, Ni

. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic SAMA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007; 109: 31–39. Epub 2006 Sep 7.

64.

Galmarini

C.M.

. Drug evaluation: forodesine-PNP inhibitor for the treatment of leukemia, lymphoma and solid tumor. Drugs. 2006; 9: 712–722

65.

Berg

S.L.

, Blaney

S.M.

, Devidas

. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol. 2005; 23: 3376–3382.